Kiniksa Pharmaceuticals Financials - Benzinga

Kiniksa Pharmaceuticals International PLC

KNSANASDAQ

Trade with Public

Trade with Public

$90.80

-1.44-1.56%

마지막 업데이트: Nov 2, 6:34 PM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Kiniksa Pharmaceuticals Financials

Kiniksa Pharmaceuticals (KNSA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $980.000M-$995.000M to $1.045B-$1.050B vs $996.102M Est

Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $980.000 million-$995.000 million to $1.045 billion-$1.050 billion vs $996.102 million estimate.

Benzinga Newsdesk

PRO
Kiniksa Pharmaceuticals Q3 EPS $0.56 Beats $0.37 Estimate, Sales $285.970M Beat $260.611M Estimate

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.37 by 51.35 percent. This is a 143.48 percent increase over earnings of $0.23 per

Benzinga Newsdesk

PRO
Kiniksa Pharmaceuticals Q2 EPS $0.30 Beats $0.27 Estimate, Sales $243.600M Beat $225.457M Estimate

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.27 by 11.11 percent. This is a 30.43 percent increase over earnings of $0.23 per share

Benzinga Newsdesk

PRO
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $930.000M-$945.000M to $980.000M-$995.000M vs $940.106M Est

Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $930.000 million-$945.000 million to $980.000 million-$995.000 million vs $940.106 million estimate.

Benzinga Newsdesk

PRO
Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $900.000M-$920.000M to $930.000M-$945.000M vs $913.245M Est

Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $900.000 million-$920.000 million to $930.000 million-$945.000 million vs $913.245 million estimate.

Benzinga Newsdesk

PRO
Kiniksa Pharmaceuticals Q1 EPS $0.27 Beats $0.19 Estimate, Sales $214.300M Beat $206.091M Estimate

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.19 by 42.11 percent. This is a 145.45 percent increase over earnings of $0.11 per share

Benzinga Newsdesk